Durvalumab-Associated Hypopituitarism
- PMID: 37921684
- DOI: 10.1097/MJT.0000000000001529
Durvalumab-Associated Hypopituitarism
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Guerrero E, Johnson DB, Bachelot A, et al. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. Eur J Cancer. 2019;113:10–13.
-
- Lupi I, Brancatella A, Cosottini M, et al. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases [published online ahead of print, 2019 Oct 12]. Endocrinol Diabetes Metab Case Rep. 2019;2019:19–0102.
-
- Levy M, Abeillon J, Dalle S, et al. Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up. J Clin Med. 2020;9:3280.
-
- Kanie K, Iguchi G, Bando H, et al. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2017;2:91–95.
-
- Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330.